Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.9 USD | -2.87% | -2.97% | -16.56% |
Financials (USD)
Sales 2024 * | 512M | Sales 2025 * | 627M | Capitalization | 3.41B |
---|---|---|---|---|---|
Net income 2024 * | -560M | Net income 2025 * | -476M | EV / Sales 2024 * | 6.13 x |
Net cash position 2024 * | 274M | Net cash position 2025 * | 337M | EV / Sales 2025 * | 4.91 x |
P/E ratio 2024 * |
-6.26
x | P/E ratio 2025 * |
-7.86
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.55% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | -0.68% | ||
1 week | -3.94% | ||
Current month | -3.78% | ||
1 month | -9.27% | ||
3 months | -17.28% | ||
6 months | +4.57% | ||
Current year | -14.41% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | 0.00% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 39.9 | -2.87% | 578,455 |
24-05-22 | 41.08 | +1.23% | 505,027 |
24-05-21 | 40.58 | -2.29% | 600,979 |
24-05-20 | 41.53 | -0.81% | 732,216 |
24-05-17 | 41.87 | -1.74% | 802,954 |
Delayed Quote Nasdaq, May 23, 2024 at 11:49 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.41% | 3.41B | |
+11.08% | 115B | |
+12.64% | 106B | |
-4.33% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-11.79% | 17.56B | |
-40.50% | 17.32B | |
+7.38% | 14.03B | |
+32.93% | 12.13B |
- Stock Market
- Equities
- RARE Stock